Hana Must SPAC 2 vs Abbott Laboratories: Fair Value & Quality
Both stocks run through our valuation models. Here is how Hana Must SPAC 2 (208370) and Abbott Laboratories (ABT) compare, as of Aug 11, 2026.
As of Aug 11, 2026, Fair Value Calculator sees Hana Must SPAC 2 as the less overvalued of the two: Hana Must SPAC 2 trades at KRW 2,840 versus a fair value of KRW 2,193 (-23%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Hana Must SPAC 2
208370.KQ · KRW · Health Care
-23%
upside to fair value
overvalued
PriceKRW 2,840
Fair ValueKRW 2,193
Quality41/100
Abbott Laboratories
ABT · USD · Health Care
-31%
upside to fair value
overvalued
Price$108
Fair Value$74.79
Quality67/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Hana Must SPAC 2Abbott Laboratories
Valuation
—P/E (TTM)27.7×
—P/S (TTM)3.89×
—P/B3.36×
—EV/EBITDA15.1×
—PEG1.47×
Profitability
56%Net margin14%
10%Operating margin13%
23%Return on equity12%
0%Return on assets6%
Growth
-9%Revenue growth (YoY)8%
3.6%Avg. growth/yr (3Y)0.5%
7.8%Avg. growth/yr (5Y)5.1%
Balance & size
—Debt / equity0.19×
$44MMarket cap$175B
expensiveGrowth qualityhealthy
Hana Must SPAC 2 leads: 4 to 3 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Hana Must SPAC 2of which business quality 41 · market factors 17Abbott Laboratoriesof which business quality 66 · market factors 51
ProfitabilityMargins and returns on capital today
37
50
Quality GrowthAre margins and returns improving?
24
47
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
30
65
Low VolatilityCalm price path (market factor)
50
83
MomentumPrice trend over the last 3–12 months (market factor)
3
40
52W MomentumDistance to the 52-week high (market factor)
5
33
Net IssuanceBuybacks instead of dilution
57
84
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Hana Must SPAC 2
DCF ModelsKRW 2,723
Earnings-BasedKRW 758
MultiplesKRW 2,571
Asset-BasedKRW 1,853
Economic ProfitKRW 2,193
Growth EarningsKRW 2,789
10 of 11 models see the stock below the current price.
Abbott Laboratories
DCF Models$73.01
Earnings-Based$29.42
Dividend Discount$39.73
Multiples$70.72
Asset-Based$20.05
Growth DCF$67.02
Economic Profit$37.49
Growth Earnings$70.25
26 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Hana Must SPAC 2
Bear KRW 1,928Fair Value KRW 2,193Bull KRW 2,193
KRW 2,840 = current price (white tick)
Abbott Laboratories
Bear $51.84Fair Value $74.79Bull $94.43
$108 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Hana Must SPAC 2 · Health Care
Quality score41 · below median
Fair value upside-23% · above median
Abbott Laboratories · Health Care
Quality score67 · Top 25%
Fair value upside-31% · below median
Bottom line
As of Aug 11, 2026, Fair Value Calculator sees Hana Must SPAC 2 as the less overvalued of the two: Hana Must SPAC 2 trades at KRW 2,840 versus a fair value of KRW 2,193 (-23%), while Abbott Laboratories trades at $108 versus $74.79 (-31%).
Abbott Laboratories has the higher quality score (67/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
